PMID- 23998577
OWN - NLM
STAT- MEDLINE
DCOM- 20140501
LR  - 20181023
IS  - 1009-2137 (Print)
IS  - 1009-2137 (Linking)
VI  - 21
IP  - 4
DP  - 2013 Aug
TI  - Expression of PML-RARalpha is up-regulated during ATRA and arsenics combined 
      induction without influence on long-term prognosis of acute promyelocytic 
      leukemia.
PG  - 872-8
LID - 10.7534/j.issn.1009-2137.2013.04.012 [doi]
AB  - The early molecular kinetics during all-trans retinoic acid (ATRA) plus 
      arsenic-based induction therapy and its prognostic value for acute promyelocytic 
      leukemia (APL) remain unclear. This study was purposed to investigate the 
      molecular and cytogenetic kinetics and its clinical significance in treatment of 
      APL with ATRA plus arsenic-based induction. The molecular and cytogenetic 
      kinetics was assessed by real-time quantitative RT-PCR and interphase 
      fluorescence in situ hybridization (FISH) in 32 newly diagnosed APL patients. The 
      results showed that the median PML-RARalpha transcript levels (PML-RARalpha/ABL) were 
      very significantly up-regulated at 14 days of induction therapy compared with 
      that of pre-treatment (40.10% vs 57.74%, P < 0.01), and then decreased at 28 days 
      of induction therapy and at the end of consolidation therapy (6.97% and 0%), 
      respectively. The total of 65.62% and 31.25% patients showed up-regulation of 
      PML-RARalpha transcript at 14 and 28 days after induction, as compared with 
      pretreatment. The PML-RARalpha copies per APL cell before treatment, and at 14 and 28 
      days after induction were calculated as 0.9, 2.2, 1.4 by the formula of 
      PML-RARA/ABL(%)x2/APL cells (%). With the median follow-up time of 22 months, 32 
      patients were still in continuous clinical remission and no molecular relapse 
      occurred. Up-regulation of PML-RARa expression during the induction had no effect 
      on outcomes of APL patients. It is concluded that up-regulation of PML-RARa 
      expression is a common event during induction therapy with ATRA plus arsenics. 
      Up-regulation of PML-RARa expression during induction therapy hasn't influenced 
      the long-term prognosis of APL.
FAU - Zhu, Hong-Hu
AU  - Zhu HH
AD  - Department of Hematology, Peking University People's Hospital; Peking University 
      Institute of Hematology, Beijing 100044, China.
FAU - Qin, Ya-Zhen
AU  - Qin YZ
FAU - Lai, Yue-Yun
AU  - Lai YY
FAU - Shi, Hong-Xia
AU  - Shi HX
FAU - Liu, Yan-Rong
AU  - Liu YR
FAU - Jiang, Bin
AU  - Jiang B
FAU - Huang, Xiao-Jun
AU  - Huang XJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhongguo Shi Yan Xue Ye Xue Za Zhi
JT  - Zhongguo shi yan xue ye xue za zhi
JID - 101084424
RN  - 0 (Arsenicals)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein)
RN  - 5688UTC01R (Tretinoin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Arsenicals/administration & dosage
MH  - Female
MH  - Humans
MH  - Leukemia, Promyelocytic, Acute/diagnosis/drug therapy/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/*metabolism
MH  - Prognosis
MH  - Tretinoin/administration & dosage
MH  - Up-Regulation/drug effects
MH  - Young Adult
EDAT- 2013/09/04 06:00
MHDA- 2014/05/03 06:00
CRDT- 2013/09/04 06:00
PHST- 2013/09/04 06:00 [entrez]
PHST- 2013/09/04 06:00 [pubmed]
PHST- 2014/05/03 06:00 [medline]
AID - 1009-2137(2013)04-0872-07 [pii]
AID - 10.7534/j.issn.1009-2137.2013.04.012 [doi]
PST - ppublish
SO  - Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Aug;21(4):872-8. doi: 
      10.7534/j.issn.1009-2137.2013.04.012.